CTIS2022-500745-24-00招募中1 期
A randomized phase II trial on the addition of dutasteride to combined androgen blockade therapy versus combined androgen blockade therapy alone in patients with recurrent and/or metastatic salivary duct carcinoma – DUCT study
Stichting Radboud University Medical Center0 个研究点目标入组 26 人开始时间: 2022年6月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Pathologically/histologically proven diagnosis of (incurable) AR+ R/M salivary duct carcinoma, Adequate cardiac function, AR positive diseases (strong expression in at least 1% of nuclei of neoplastic cells based on central IHC review), Measurable disease per RECIST version 1.1 at baseline, Age = 18 years, Written informed consent must be given according to national/local regulation, Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, Adequate bone marrow function: (WBC = 3.5x10^9 /L; Absolute neutrophil count (ANC) = 1.5x10^9/L; Hemoglobin = 6.20 mmol/L; Platelet count = 100x10^9/L), Adequate liver function: (Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5 times upper limit of normal (ULN) OR = 5.0 times ULN for patients with liver metastases; Bilirubin = 1.5 times ULN. For patients known with Gilbert’s Syndrome = 3.0 times ULN is permitted), Adequate renal function: (Serum creatinine level = 1.5 times ULN or calculated creatinine clearance = 30 mL/min based on CKD-EPI-GFR)
排除标准
- •Patients with history of allergic reactions attributed to compounds of similar chemical or biological composition to goserelin, bicalutamide or dutasteride, Concurrent treatment with any other anti-cancer therapy within the last 4 weeks before inclusion, Curative radiation therapy within the last 4 weeks before inclusion or palliative radiation therapy 1 week before start of study, Any condition which, in the opinion of the investigator, would preclude participation in this clinical study, Patients with peanut or soy allergy (dutasteride capsules contain lecithin which may contain soy oil), Patients who do not have adequate swallowing capacity, Patients familiar with Long QT-syndrome (LQTS), Patients (M/F) with reproductive potential not implementing adequate contraceptive measures, Patients that are pregnant or lactating, Patients with uncontrolled illness including: Cardiovascular disorders, including symptomatic congestive heart failure, unstable angina pectoris, or serious cardiac arrhythmias; Uncontrolled hypertension (defined as sustained systolic BP > 160 mm Hg, or diastolic BP > 100 mm Hg. Unless evidence of white-coat hypertension), Stroke (including TIA), myocardial infarction, or other ischemic event within 6 months before inclusion; Serious active infections ., Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation, Concomitant (or within 6 months before inclusion) administration of any 5-alpha reductase inhibitor, i.e. dutasteride or finasteride
研究者
相似试验
进行中（未招募）
1 期
A randomised phase 2 trial investigating the additional benefit of hydroxychloroquine (HCQ) to short course radiotherapy (SCRT) in patients aged 70 years and older with high grade gliomas (HGG)EUCTR2012-000091-41-GBniversity College London57
进行中（未招募）
不适用
A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer - GeparSixtopatients with triple-negative breast cancer, patients with HER2-positive early breast cancerMedDRA version: 14.1Level: LLTClassification code 10021976Term: Inflammatory breast cancer stage IVSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10063104Term: Tubular breast cancer stage IISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10022882Term: Invasive ductal breast cancerSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10028061Term: Mucinous breast cancer stage IISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10063105Term: Tubular breast cancer stage IIISystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10021974Term: Inflammatory breast cancerSystem Organ Class: 100000004864EUCTR2011-000553-23-DEGerman Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
尚未招募
2 期
To study the effect of Deuterium depleted water in patients receiving neoadjuvant chemotherapy (NACT) for triple negative (TNBC) or HER2 positive breast cancerCTRI/2024/06/068676Tata Memorial Centre
进行中（未招募）
不适用
A phase II clinical trial on the combination of dabrafenib and trametinib for BRAF-inhibitor pretreated patients with advanced BRAF V600 mutant melanomaadvanced BRAF V600 mutant melanomaMedDRA version: 16.1Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10025670Term: Malignant melanoma stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: HLTClassification code 10027156Term: Skin melanomas (excl ocular)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10066600Term: Melanoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10027480Term: Metastatic malignant melanomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-004966-33-BEZ Brussel
已完成
不适用
A randomized phase II study investigating the addition of the specific cox-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC-IV epithelial ovarian fallopian tube or primary peritoneal carcinomasCancerISRCTN30851756VU University Medical Center (The Netherlands)200